Atherogenic autoantigen: Oxidized LDL complexes with β2-glycoprotein I

Eiji Matsuura, Kazuko Kobayashi, Takao Koike, Yehuda Shoenfeld, Munther A. Khamashta, Graham R.V. Hughes

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


β2-Glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies present in patients with antiphospholipid syndrome (APS). In 1997, we demonstrated that β2-GPI specifically binds to CU2+-oxidized low-density lipoprotein (oxLDL) and that the β2-GPI-oxLDL complex is subsequently targeted by anti-β2-GPI antibodies in vitro. Then ligands for β2-GPI were purified from oxLDL and characterized as omega-carboxylated 7-ketocholesteryl esters, such as 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) and 7-ketocholesteryl-12-carboxy (keto) dodecanoate (oxLig-2). These ligands mediate to form oxLDL-β2-GPI complexes, and the complexes are taken up avidly by macrophages via anti-β2-GPI autoantibody-mediated phagocytosis. We recently demonstrated that appearance of autoantibodies against a complex of β2-GPI and oxLig-1 are highly associated with a history of arterial thrombosis. Serum oxLDL-β2-GPI complex and their IgG immune complexes are also risk factors arterial thrombosis in APS patients. There is increasing circumstantial evidence of autoimmune mechanism involving β2-GPI and oxLDL in the atherogenesis in APS.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
Issue number1
Publication statusPublished - 2003

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology


Dive into the research topics of 'Atherogenic autoantigen: Oxidized LDL complexes with β2-glycoprotein I'. Together they form a unique fingerprint.

Cite this